38.22
+1.1(+2.96%)
Currency In HKD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8989
First IPO Date
June 14, 2019
| Name | Title | Pay | Year Born |
| Ms. Huijuan Zhong | Chairlady, Chief Executive Officer & President | 12.92M | 1961 |
| Dr. Aifeng Lyu | Executive Director | 3.2M | 1977 |
| Ms. Yuan Sun | Executive Director | 7.93M | 1987 |
| Mr. Chuanhe Xu | Senior Vice President | 0 | 1964 |
| Dr. Chih-Hung Lee | Chief of Science Officer | 0 | 1960 |
| Mr. Min Hu | Vice President & Chief Financial Officer | 0 | 1977 |
| Dr. Shan Jiang | Chief Technology Officer | 0 | 1970 |
| Mr. Weiyong Sun | Chief Business Officer | 0 | 1971 |
| Dr. Xiaoqing Zhang | Chief Medical Officer | 0 | 1974 |
| Ms. Shengli Zhong | Joint Company Secretary & Senior Vice President | 0 | 1968 |
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.